JNCE Jounce Therapeutics

Jounce Therapeutics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020

Jounce Therapeutics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020

CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2020 financial results and provide a corporate update before market open on Wednesday, May 6, 2020. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET.

Conference Call and Webcast

To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 4044098. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at . The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce has three development-stage programs, two of which are clinical-stage, vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and a biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014 will be initiated mid-year 2020. The next development candidate to emerge from Jounce’s Translational Science Platform is JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. JTX-1811 is currently in IND-enabling activities. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene Corporation, a wholly-owned subsidiary of Bristol-Myers Squibb Company. For more information, please visit .

Investor and Media Contact:

Komal Joshi

Jounce Therapeutics, Inc.

(857) 320-2523

EN
29/04/2020

Underlying

JNCEJounce Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Jounce Therapeutics

 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 03-Apr-2023 / 12:25 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trus...

April 3, 2023 1 EN
 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Termination of Proposed Business Combination of Jounce Therapeutics, I...

Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce’s Board of Directors to withdraw the recommendation for the ...

April 3, 2023 1 EN
 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 30-March-2023 / 13:21 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the tr...

March 30, 2023 1 EN
 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 29-March-2023 / 13:22 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the tr...

March 29, 2023 1 EN
 PRESS RELEASE
Free
JNCE Jounce Therapeu...

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 28-March-2023 / 13:33 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the tr...

March 28, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch